Market news

Qiagen (NYSE:QGEN) just received U.S. FDA clearance for its QIAstat-Dx gram-negative bloodstream infection panel, giving American laboratories full access to the company’s rapid sepsis testing portfolio in a single automated system. Qiagen’s latest FDA clearance lands after a period of mixed trading, with the share price up 15.1% over the past 90 days but still down 5.4% year to date, while the 1-year total shareholder return of 3.2% points to modest longer term gains. Scan how Qiagen’s...

Earlier this week, QIAGEN announced that U.S. labs now have access to its full QIAstat-Dx bloodstream infection portfolio after FDA clearance of a one-hour gram-negative bacteria and antibiotic resistance panel, complementing an existing gram-positive and fungal panel and expanding its syndromic infectious disease testing menu. This clearance materially broadens QIAGEN’s coverage to 33 bloodstream pathogen targets and 28 resistance markers, reinforcing the clinical relevance of its automated...

GERMANTOWN, Md. & VENLO, Netherlands, September 28, 2026--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that U.S. laboratories now have access to the complete QIAstat-Dx bloodstream infection portfolio following clearance of a new panel by the U.S. Food and Drug Administration (FDA).

QIAGEN NV (QGEN) launched QIAmini, a compact automated sample preparation system designed for resear

QGEN's test menu expansion and strategic partnerships support growth, but cautious spending and competition may weigh on near-term gains.

VENLO, Netherlands, September 18, 2026--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it will hold an Extraordinary General Meeting of Shareholders on November 6, 2026, at 2:00 p.m. CET.

Detailed price information for Qiagen N.V. (QGEN-N) from The Globe and Mail including charting and trades.

Qiagen (NYSE:QGEN) shares gained 4% on Thursday morning following a media report that several private equity firms are considering potential offers for the molecular testing company. German publication Manager Magazin reported that TPG and Bain Capital are among the firms weighing bids for Qiagen, although it did not identify sources for the information.

Detailed price information for Qiagen N.V. (QGEN-N) from The Globe and Mail including charting and trades.

Tipranks Press Release.

QIAGEN NV (QGEN) has an average rating of overweight and mean price target of $45.83, according to a

Qiagen (QGEN) has drawn fresh attention after Q2 2026 adjusted earnings and net sales came in above consensus, even as estimates had recently drifted lower, and management reaffirmed its full year outlook. The Q2 beat and reaffirmed guidance contrast with a mixed share price backdrop for Qiagen, with the stock closing at US$43.47 after a daily share price return that slipped 0.89% but a 90 day share price return of 18.51% pointing to improving momentum. Capitalize on Qiagen's earnings...

Detailed price information for Qiagen N.V. (QGEN-N) from The Globe and Mail including charting and trades.

In late August 2026, Qiagen launched QIAsymphony Connect, an IVD-compliant automated nucleic acid extraction platform with FDA and EUDAMED listings, while also announcing a CEO transition to Jon Pratt from September 1 and reporting Q2 2026 results that exceeded analyst expectations with reaffirmed guidance. The combination of a next-generation automation platform, leadership change and better-than-expected quarterly performance highlights how Qiagen is tightening its focus on high-throughput...

Detailed price information for Qiagen N.V. (QGEN-N) from The Globe and Mail including charting and trades.

Opportunities center on NGS, metagenomic profiling, portable field tests and cloud analytics, driven by viral outbreaks, precision agriculture, biosecurity and demand for early detection. Plant Virome Diagnostics Market Plant Virome Diagnostics Market Dublin, Sept. 01, 2026 (GLOBE NEWSWIRE) -- The "Plant Virome Diagnostics Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global plant virome diagnostics market is experiencing strong growth as agricultural producers, re

Detailed price information for Qiagen N.V. (QGEN-N) from The Globe and Mail including charting and trades.

Detailed price information for Qiagen N.V. (QGEN-N) from The Globe and Mail including charting and trades.

Detailed price information for Qiagen N.V. (QGEN-N) from The Globe and Mail including charting and trades.

Qiagen N.V. (NYSE:QGEN) announced on August 10 that the U.S. FDA cleared its QIAstat-Dx BCID GPF Plus AMR Panel, marking the company’s first entry into the U.S. bloodstream infection testing market. Operating on the QIAstat-Dx platform, which boasts over 5,200 global placements, the automated panel detects 20 gram-positive bacterial and fungal targets, alongside 10 genetic […]

Qiagen (QGEN) takeover talks heat up as two parties start due diligence near $50/share; EQT and KKR reportedly exploring bids.

Jonathan Pratt will take over the role on Sept. 1. The announcement ends Qiagen’s nearly 10-month search for a new chief executive.

VENLO, Netherlands, August 24, 2026--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Jonathan M. Pratt has been appointed Chief Executive Officer, effective September 1, 2026. He brings to QIAGEN more than 25 years of international leadership experience across life sciences, laboratory technologies and healthcare.

Detailed price information for Qiagen N.V. (QGEN-N) from The Globe and Mail including charting and trades.

Detailed price information for Qiagen N.V. (QGEN-N) from The Globe and Mail including charting and trades.

Qiagen (QGEN) has drawn fresh attention after surpassing its own sales and EPS outlook for Q2 2026 and reaffirming full year guidance, along with FDA clearance for its QIAstat Dx BCID GPF Plus AMR Panel. See our latest analysis for Qiagen. The recent Q2 beat, reaffirmed guidance and FDA clearance appear to have supported sentiment in Qiagen, with the stock at US$43.23 and a 90 day share price return of 31.08% contrasting with a year to date share price decline of 9.12% and a 1 year total...

Qiagen (NYSE:QGEN) walked into its second quarter of 2026 bracing investors for a roughly 2% sales decline. Instead, net sales came in flat at $535 million on August 6, and adjusted diluted EPS hit $0.62, both ahead of the company’s own outlook. For a diagnostics and life sciences supplier still working through the loss of […]

Earlier this week, QIAGEN reported second-quarter 2026 results showing essentially flat year-on-year sales at US$535.04 million but higher net income of US$103.4 million, alongside shareholder-approved changes to its Articles that enable a reverse stock split and a capital repayment of up to US$200 million. On August 10, 2026, the company also secured U.S. FDA clearance for its QIAstat-Dx BCID GPF Plus AMR Panel, moving its QIAstat-Dx platform into bloodstream infection diagnostics and...

Motley Fool Press Release.

Detailed price information for Qiagen N.V. (QGEN-N) from The Globe and Mail including charting and trades.

Detailed price information for Qiagen N.V. (QGEN-N) from The Globe and Mail including charting and trades.

Evaluate Qiagen's (QGEN) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.

GERMANTOWN, Md. & VENLO, Netherlands, August 10, 2026--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared the QIAstat-Dx BCID GPF Plus AMR Panel, the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance.

Detailed price information for Qiagen N.V. (QGEN-N) from The Globe and Mail including charting and trades.

Detailed price information for Qiagen N.V. (QGEN-N) from The Globe and Mail including charting and trades.